LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics.


LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases.


LEXEO obtains exclusive rights to three investigational AAV-mediated gene therapy programs for rare cardiac disorders, all of which have no existing disease-modifying treatments available.


Strategic acquisition expands LEXEO’s rare cardiac gene therapy pipeline making it one of the most extensive in the field.



LEXEO Aquires Stelios Therapeutics
.pdf
Download PDF • 193KB